Mylan announced that it has received final approval from the Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Metformin Hydrochloride Extended-Release Tablets USP, the generic version of Fortamet (Watson).
The treatment is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is available in 500mg and 1000mg dosage strengths.
Metformin hydrochloride, a biguanide, reduces hepatic glucose production and intestinal glucose absorption. It also improves insulin sensitivity and peripheral glucose uptake and utilization.
For more information call 724-514-1968 or visit Mylan.com.